Abstract
Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity. Its primary mechanism of action is increased satiety, although some evidence also suggests increased energy expenditure could play a role in sibutramine-induced weight loss. It has established general efficacy in long-term trials, with clinically-approved doses of 10 and 15 mg. Sibutramine has also been studied in a number of unique populations, including obese controlled hypertensives, diabetics and ethnic minorities, further establishing its effectiveness. However, it does have a consistent effect of increasing blood pressure and pulse. Thus, blood pressure and heart rate should be monitored in patients using sibutramine and it may not be applicable in obese patients with significant cardiovascular disease.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Adolescent
-
Adrenergic Uptake Inhibitors / adverse effects
-
Adrenergic Uptake Inhibitors / pharmacology
-
Adrenergic Uptake Inhibitors / therapeutic use
-
Appetite Depressants / adverse effects
-
Appetite Depressants / pharmacology
-
Appetite Depressants / therapeutic use*
-
Cardiovascular System / drug effects
-
Clinical Trials as Topic
-
Cyclobutanes / adverse effects
-
Cyclobutanes / pharmacology
-
Cyclobutanes / therapeutic use*
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / drug therapy
-
Humans
-
Obesity / complications
-
Obesity / drug therapy*
-
Racial Groups
-
Selective Serotonin Reuptake Inhibitors / adverse effects
-
Selective Serotonin Reuptake Inhibitors / pharmacology
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
Substances
-
Adrenergic Uptake Inhibitors
-
Appetite Depressants
-
Cyclobutanes
-
Serotonin Uptake Inhibitors
-
sibutramine